In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to AMP by ecto-phosphodiesterase, and metabolism of AMP to adenosine by ecto-5Ј-nucleotidase. Although much is known about ecto-5Ј-nucleotidase, the renal ecto-phosphodiesterase remains uncharacterized. We administered cAMP (10 M in the perfusate) to 12 different groups of perfused kidneys. AMP was measured in perfusate using ion trap mass spectrometry. In control kidneys (n ϭ 19), basal renal secretion rate of AMP was 0.49 Ϯ 0.08 and increased to 3.0 Ϯ 0.2 nmol AMP/g kidney weight/min during administration of cAMP. A broad-spectrum phosphodiesterase (PDE) inhibitor (1,3-isobutyl-1-methylxanthine, 300 M, n ϭ 6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n ϭ 6) significantly attenuated cAMPinduced AMP secretion by 60 and 74%, respectively. Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 M), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 M], PDE3 (milrinone, 10 M; cGMP, 10 M), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 M), PDE5 and PDE6 (zaprinast, 30 M), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 M] did not alter renal ecto-phosphodiesterase activity. Administration of a concentration (100 M) of dipyridamole that blocks PDE8 inhibited ecto-phosphodiesterase activity (by 44%). However, a lower concentration of dipyridamole (3 M) that blocks PDE9, PDE10, and PDE11, but not PDE8, did not inhibit ecto-phosphodiesterase activity. These data support the conclusion that renal ecto-phosphodiesterase activity is not mediated by PDE1, PDE2, PDE3, PDE4, PDE5, PDE6, PDE7, PDE9, PDE10, or PDE11 and is inhibited by high concentrations of dipyridamole. Ecto-phosphodiesterase has some pharmacological characteristics similar to PDE8.Multiple biochemical pathways provide for the biosynthesis of adenosine. The well characterized pathways include the intracellular ATP pathway (intracellular dephosphorylation of ATP to adenosine) (Schrader, 1991), the extracellular ATP pathway (metabolism of released adenine nucleotides to adenosine by ecto-enzymes) (Gordon, 1986), and the transmethylation pathway (the hydrolysis of S-adenosyl-L-homocysteine to L-homocysteine and adenosine by the enzyme S-adenosyl-L-homocysteine-hydrolase) (Lloyd et al., 1988). The intracellular ATP pathway is activated when energy demand exceeds energy supply (Schrader, 1991); the extracellular ATP pathway is engaged when adenine nucleotides are released during sympathoadrenal activation, platelet aggregation, or activation of cardiovascular cells by clotting factors, neutrophil interactions, and catecholamines (Pearson and Gordon, 1979;Pearson et al., 1980;LeRoy et al., 1984); and the transmethylation pathway is triggered by methylation reactions involving S-adenosyl-L-methionine as the methyl donor (Lloyd et al., 1988;Deussen et al., 1989). These three well described routes of adenosine biosynthesis are not well suited for physiological modulation of extracell...